Danish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Side 1 fra 22 resultater
An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
BACKGROUND
Pseudobulbar affect (PBA) is associated with neurological disorders or injury affecting the brain, and characterized by frequent, uncontrollable episodes of crying and/or laughing that are exaggerated or unrelated to the patient's emotional state. Clinical trials establishing
[Plasma level studies of quinidine retard, their significance for dosage and onset of effect].
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
A new sustained-action preparation of quinidine-bisulfate (BM-Chinidin Retard) was investigated in 21 patients. After a single oral dose of 1 g peak plasma levels are reached within 3-4 hours with an unsubstantial decrease during the following 4 hours. After 2 g in three divided doses within 12
Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
OBJECTIVE
This study aimed to assess potential efficacy and safety of dextromethorphan/quinidine (DMQ) in prophylactic treatment of migraine in patients with multiple sclerosis (MS) with superimposed pseudobulbar affect (PBA).
METHODS
Multiple sclerosis patients with superimposed PBA and comorbid
Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
BACKGROUND
Dextromethorphan (DM) / quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based on efficacy and safety trials in patients with PBA caused by amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke,
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
BACKGROUND
Phase 3 trials supporting dextromethorphan/quinidine (DM/Q) use as a treatment for pseudobulbar affect (PBA) were conducted in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). The PRISM II study provides additional DM/Q experience with PBA secondary to
Fatal quinidine-induced thrombocytopenia following open-heart surgery.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Three patients developed quinidine-induced thrombocytopenia within 3 months of our initiating quinidine therapy after open-heart surgery. One patient recovered from thrombocytopenic purpura after quinidine was discontinued. The 2 other patients presented with thrombocytopenic purpura and gingival
Propafenone versus quinidine slow-release for the treatment of chronic ventricular arrhythmias.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
The efficacy and side-effects of oral propafenone 300 mg b.i.d. were compared to those of quinidine slow-release 800 mg b.i.d. in a randomized double-blind placebo controlled cross-over study in 12 patients with symptomatic premature ventricular complexes (PVCs). Furthermore during steady-state the
Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
BACKGROUND
Pain associated with diabetic peripheral neuropathy (DPN) has a substantial negative impact on patients' quality of life.
OBJECTIVE
The primary objective of this study was to evaluate the tolerability of capsules containing dextromethorphan (DM) and quinidine (Q) in patients with painful
Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
The antiarrhythmic efficacy and safety of oral flecainide acetate and quinidine sulfate were compared in a double-blind, 16-center parallel trial involving 280 patients with chronic premature ventricular complexes (PVCs). Eighty-five percent of the flecainide patients had at least 80% suppression of
Intravenous dextromethorphan/quinidine inhibits activity of dura-sensitive spinal trigeminal neurons in rats.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
BACKGROUND
Migraine is a chronic neurological disorder characterized by episodes of throbbing headaches. Practically all medications currently used in migraine prophylaxis have a number of substantial disadvantages and use limitations. Therefore, the further search for principally new prophylactic
An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Dextromethorphan (DM)/quinidine (Q) is an approved treatment for pseudobulbar affect (PBA) based on trials in amyotrophic lateral sclerosis or multiple sclerosis. PRISM II evaluated DM/Q effectiveness and tolerability for PBA secondary to dementia, stroke, or traumatic brain injury; dementia cohort
Falciparum malaria--present day problems. An experience with 425 cases.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Clinical details and present day problems encountered in 425 cases of falciparum malaria (PF) are reported. 10.11% had taken chloroquine prior to reporting to us. Parasitic count done in 23.05% cases lacked correlation with severity of disease. Pattern of fever varied markedly but 5.4% were afebrile
Involvement of gap junction channels in the pathophysiology of migraine with aura.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Migraine is a common, recurrent, and disabling primary headache disorder with a genetic component which affects up to 20% of the population. One third of all patients with migraine experiences aura, a focal neurological disturbance that manifests itself as visual, sensitive or motor symptoms
Moricizine: a new class I antiarrhythmic.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of the Class I antiarrhythmic agent moricizine hydrochloride are reviewed. Moricizine is chemically similar to the phenothiazines but does not appear to block dopaminergic receptors. Its major
[Antiarrhythmic effect of disopyramide in ventricular extrasystole and auricular fibrillation].
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Disopyramide (B 712) was tested in 39 patients with chronic arrhythmias of different kind: 23 cases with atrial fibrillation, 16 cases with ventricular ectopic beats, two cases with supraventricular tachycardias. The effect of disopyramide was compared to a pretreatment with one or several
Den mest komplette database med medicinske urter understøttet af videnskab
- Arbejder på 55 sprog
- Urtekurer, der understøttes af videnskab
- Urtegenkendelse ved billede
- Interaktivt GPS-kort - tag urter på stedet (kommer snart)
- Læs videnskabelige publikationer relateret til din søgning
- Søg medicinske urter efter deres virkninger
- Organiser dine interesser og hold dig opdateret med nyhedsundersøgelser, kliniske forsøg og patenter
Skriv et symptom eller en sygdom, og læs om urter, der kan hjælpe, skriv en urt og se sygdomme og symptomer, den bruges mod.
* Al information er baseret på offentliggjort videnskabelig forskning
